Beam Therapeutics
The Manager, Regulatory Affairs will support advancement of Beam’s portfolio of advanced genetic medicines by developing and implementing global regulatory strategies. This role partners with the Regulatory Lead and cross-functional teams to ensure programs meet evolving global regulatory requirements and progress toward clinical and commercial goals. The position contributes to regulatory planning, submission preparation, and interactions with health authorities in a fast-paced biotech environment.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2017
Beam Therapeutics is a clinical-stage biotechnology company based in Cambridge, MA, pioneering precision genetic medicines using its proprietary base editing platform to make precise single‑base DNA changes without creating double‑strand breaks. The company advances both in vivo and ex vivo programs across hematology, rare genetic diseases, and oncology, moving several candidates toward clinical development. Beam combines engineered editors, delivery technologies, and extensive safety profiling to create durable, potentially one‑time treatments and partners with academic and industry collaborators to accelerate translation.
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
10 hours ago
Beam Therapeutics (BEAM) Leverages New Financing And IP Control Is Its Gene-Editing Edge Strengthening?
3 days ago
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Beam Therapeutics.
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
2 weeks ago